Allergan's Tribe Deal Over Restasis Sparks Ire From Legislators
Executive Summary
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
You may also be interested in...
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach
The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.